Graves ophthalmopathy treatment market is expected to reach US$ 3.01 Billion by 2033 | Top Companies are Amgen Inc., Immunovant, Inc., Viridian Therapeutics, Inc.

The global graves ophthalmopathy treatment market size reached US$ 2.09 Billion in 2024 and is expected to reach US$ 3.01 Billion by 2033, growing at a CAGR of 4.2% during the forecast period 2025-2033.

Graves Ophthalmopathy Treatment Market involves therapies for thyroid-associated eye disease, including steroids, biologics, and surgical interventions. Growth is driven by rising autoimmune disorders, clinical awareness, and new treatment development. Hospitals, endocrinology, and ophthalmology clinics are key end-users. Innovations focus on targeted therapies, minimally invasive procedures, and biologics. Regulatory approvals and clinical guidelines support adoption. Increasing prevalence of thyroid disorders fuels market expansion. Patient-centric therapies enhance outcomes.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Graves Ophthalmopathy Treatment Market Landscape:- https://datamintelligence.com/download-sample/graves-ophthalmopathy-treatment-market?Ranjith

☛ Graves Ophthalmopathy Treatment Market Recent Developments 2025:

United States: Recent Industry Developments

✅ In September 2025, Horizon Therapeutics plc (now part of Amgen Inc.) announced new clinical data for TEPEZZA® (teprotumumab-trbw) showing sustained efficacy in reducing proptosis and inflammation in chronic Thyroid Eye Disease (TED) patients. The therapy remains the only FDA-approved biologic specifically for TED treatment in the U.S.

✅ In July 2025, Viridian Therapeutics, Inc. reported positive results from its Phase 2 trial of VRDN-001, an anti-IGF-1R monoclonal antibody designed to rival TEPEZZA®. The treatment demonstrated rapid improvement in eye bulging and diplopia, with fewer infusion-related adverse events.

✅ In May 2025, Immunovant, Inc. expanded its batoclimab (IMVT-1401) trial for moderate-to-severe Graves' Ophthalmopathy. The drug, targeting neonatal Fc receptor (FcRn), aims to reduce pathogenic IgG antibodies and inflammation driving TED progression.

✅ In April 2025, Regeneron Pharmaceuticals, Inc. initiated preclinical development of a next-generation IGF-1R/TSHR dual antagonist for autoimmune thyroid eye diseases, aiming for greater disease modulation and longer therapeutic durability.

Japan: Recent Industry Developments

✅ In August 2025, Chugai Pharmaceutical Co., Ltd. (a member of the Roche Group) announced collaborative research with The University of Tokyo Hospital on novel Fc-engineered monoclonal antibodies targeting IGF-1R pathways implicated in Graves' Ophthalmopathy.

✅ In July 2025, Ono Pharmaceutical Co., Ltd. began exploratory research on small-molecule TSH receptor inhibitors intended to suppress orbital fibroblast activation, a key driver of inflammation and tissue remodeling in TED.

✅ In June 2025, Takeda Pharmaceutical Company Ltd. initiated a partnership with Kyoto University to develop RNA-based therapeutics aimed at downregulating TSHR gene expression, representing a potential breakthrough in targeted Graves' eye disease therapy.

✅ In May 2025, Santen Pharmaceutical Co., Ltd., known for its ophthalmic expertise, launched early-stage development of an anti-fibrotic ophthalmic formulation to mitigate orbital tissue scarring in advanced TED cases.

☛ Graves Ophthalmopathy Treatment Market Competitive Landscape:

Amgen Inc., Immunovant, Inc., Viridian Therapeutics, Inc., Argenx, Tourmaline Bio, Inc., F. Hoffmann-La Roche Ltd and Sling Therapeutics, among others.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/graves-ophthalmopathy-treatment-market?Ranjith

☛ Segments Covered in the Graves Ophthalmopathy Treatment Market:

By Medication:
Monoclonal Antibodies | Corticosteroids | Antithyroid Medications | Others

By Disease Severity:
Mild | Moderate | Severe

By End-User:
Hospitals | Specialty Clinics | Academic and Research Institutes | Others

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Graves Ophthalmopathy Treatment Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=graves-ophthalmopathy-treatment-market?Ranjith

☛ Regional Analysis for Graves Ophthalmopathy Treatment Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.